Skip to main content

Day: March 31, 2023

Brunswick Exploration Announces Closing of Final Tranche of Non-Brokered Private Placement for Total Proceeds of $2.08M

MONTREAL, March 31, 2023 (GLOBE NEWSWIRE) — Brunswick Exploration Inc. (“Brunswick” or the “Corporation”) (TSX-V: BRW) is pleased to announce that it has closed a second and final tranche of its non-brokered private placement, previously announced on February 13, 2023, for additional gross proceeds of $587,500.45 consisting of the issuance of 691,177 units of the Corporation (each, a “Unit”) at a price of $0.85 per Unit (the “Offering”). In the aggregate, 2,448,472 Units were issued under the non-brokered private placement, for aggregate gross proceeds of $2,081,201.20. Killian Charles, President & CEO commented: “Brunswick Exploration now has in excess of $16M available to continue its growth strategy and launch one of the largest lithium grassroot exploration program in the world. With ongoing drilling at Anatacau West and...

Continue reading

Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K

IRVINE, Calif., March 31, 2023 (GLOBE NEWSWIRE) — Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced plans to file a Form 12b-25 with the U.S. Securities and Exchange Commission regarding its Annual Report on Form 10-K and reports preliminary financial results for the full year ended December 31, 2022. The Company is completing its final review of the information required to be presented for the relevant period. The Form 12b-25 provides the Company with an additional 15 calendar days to complete its assessment and allows its independent registered public accounting firm extra time to complete its audit of the Company’s financial statements before filing its Form 10-K reports. The Company currently anticipates filing the 2022 Form 10-K as soon as practicable and expects that, in compliance...

Continue reading

SAB Biotherapeutics Provides Company Update for Full Year 2022

SIOUX FALLS, S.D., March 31, 2023 (GLOBE NEWSWIRE) — SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulin (hIgG) antibodies, also known as fully-human polyclonal antibodies, without the need for human donors, today reported financial results for the full year ended December 31, 2022, and provided a company update. “I am pleased to share the meaningful progress SAB has made this past year advancing our groundbreaking, proprietary immunotherapy platform, a powerful approach and the only one in the world that generates targeted and fully-human immunoglobulin antibodies without the need for human donors. We continue to use this platform to create first-of-its-kind approaches and set new...

Continue reading

Enservco Corporation Reports 2022 Fourth Quarter and Full Year Financial Results

Q4 revenue up 59% YOY to $6.5 million from $4.1 millionSeventh consecutive quarter of YOY revenue growth following drilling downturn and pandemic impact that began in 2020Q4 net loss improves to $1.7 million from $3.1 millionQ4 adjusted EBITDA turns positive at $17,000 vs. loss of $2.0 millionFull year revenue up 41% YOY to $21.6 million from $15.3 million due to revenue gains in both production and completion segmentsFull year net loss improves to $5.6 million from $8.1 millionFull year adjusted EBITDA improves to loss of $2.6 million from loss of $6.1 millionFebruary 2023 public offering raised approximately $3.5 million in gross proceedsExecutive Chairman’s investment firm converted $1.1 million of convertible debt to common stock with plans for future fixed price conversions pending stockholder approval at upcoming...

Continue reading

Goodness Growth Holdings Announces Fourth Quarter and Full Year 2022 Results

– 2022 revenue of $74.6 million increased 37.1% YOY and 57.8% excluding discontinued operations – – Q4 revenue of $19.0 million increased 39.4% YoY and 55.8% excluding discontinued operations – – Company amends credit facility with Green Ivy to remove amortization schedule and extend maturity date – MINNEAPOLIS, March 31, 2023 (GLOBE NEWSWIRE) — Goodness Growth Holdings, Inc. (“Goodness Growth” or the “Company”) (CSE: GDNS; OTCQX: GDNSF), a cannabis company committed to providing safe access, quality products and great value to its customers, today reported financial results for its fourth quarter and full year ended December 31, 2022. Key financial results are presented below in summary form with supporting commentary and discussion from management of certain key operating metrics which the Company uses...

Continue reading

MEGA MATRIX CORP. Reports Fiscal Year 2022 Financial Results

PALO ALTO, Calif., March 31, 2023 (GLOBE NEWSWIRE) — Mega Matrix Corp. (“MPU” or the “Company”) (NYSE American: MPU), today announced financial results for its fiscal year ended December 31, 2022. Financial HighlightsThe Company had cash and cash equivalents of $7.3 million, and total liquidity (defined as cash equivalents and restricted cash, stable coins and digital assets) of approximately $10.7 million, as of December 31, 2022. Total assets were $12.6 million as of December 31, 2022. Equity attributable to MPU’s shareholders amounted to $8.0 million as of December 31, 2022.The Company closed two private placements during October 2022 through February 2023, pursuant to which the Company raised gross proceeds of $11 million by issuance of 9,479,999 shares of common stock.Operational HighlightsTreasury...

Continue reading

Gulf Resources Reports 2022 Results and Provides Business and Strategic Plan Outlook

SHOUGUANG, China, March 31, 2023 (GLOBE NEWSWIRE) — Gulf Resources, Inc. (Nasdaq: GURE) (“Gulf Resources”, “we,” or the “Company”), a leading manufacturer of bromine, crude salt and specialty chemical products in China, today reports results for fiscal year 2022 and provides updates on its business segments and corporate strategies. During 2022, revenues increased 20% to $66,094,486. Gross profits increased 34% to $37,425,334. Profits from operations increased 216% to $16,481,696. Net income per share was $1.00 versus a loss of ($0.09) per share. Despite negative foreign currency translation adjustment of $24,886,118, which impacted all balance sheet items, ending cash was $108,226,214 ($10.37* per share), working capital was $107,649,606. Net net cash (cash minus all liabilities) per share was...

Continue reading

Splash Beverage Group Reports 2022 Fourth Quarter and Full Year Financial Results

Fort Lauderdale, FL, March 31, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Splash Beverage Group, Inc. (NYSE American: SBEV) (“Splash” or the “Company”), a portfolio company of leading beverage brands, today reported financial results for the  fourth quarter and full year period ended December 31, 2022.  Investors are encouraged to read the Company’s annual report on Form 10-K which was filed with the Securities and Exchange Commissions (the “SEC”), contains additional information, and is posted at https://splashbeveragegroup.com/. Fourth Quarter and Full Year Financial Performance ·       Revenues for the fourth quarter were $4.79 million compared to $3.06 million in the prior year period, an increase of 56%.  Full-year gross revenues were $19.0 million compared to $11.8 million in the prior year period,...

Continue reading

LMP Automotive Holdings, Inc. today announced it has closed on the sale of its KIA and Subaru Dealerships in Mount Hope, WV and Provided a Corporate Update

FORT LAUDERDALE, March 31, 2023 (GLOBE NEWSWIRE) — LMP Automotive Holdings, Inc. (“LMP” or the “Company”), an e-commerce and facilities-based automotive retailer in the United States, today announced it has closed on the sale of its KIA and Subaru dealerships in Mount Hope, WV. ABOUT LMP AUTOMOTIVE HOLDINGS, INC. LMP Automotive Holdings, Inc. offers a wide array of products and services fulfilling the entire vehicle ownership lifecycle, including new and used vehicles, finance and insurance products and automotive repair and maintenance.Our proprietary e-commerce technology and strategy are designed to disrupt the industry by leveraging our experienced teams, growing selection of owned inventories and physical logistics network. We seek to provide customers with a seamless experience both online and in person. Our physical logistics...

Continue reading

Entera Bio Provides 2022 Corporate Milestones and Financial Results for the Year Ended December 31, 2022

JERUSALEM, March 31, 2023 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced a summary of 2022 corporate achievements and financial results for the year ended December 31, 2022. “The year 2022 and 2023 year to date, has been a critical time for Entera, during which focus, optimization and execution across our organization has been paramount to adequately prepare our EB613 program to become phase 3 ready, from a clinical, regulatory, and manufacturing standpoint. EB613 (oral PTH(1-34), teriparatide) is positioned as the first potential daily tablet anabolic therapy for the treatment of post-menopausal women with low Bone Mineral Density (BMD) and osteoporosis. In addition, we have continued to harness our...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.